Bempedoic Acid: From Guidelines to the Real World

Q: What is the clinical evidence from this study?

Study design: Review. Population: Dyslipidemia and Atherosclerotic Cardiovascular Disease. Intervention: Bempedoic acid vs. Placebo or standard lipid-lowering therapy.

Q: What does this research mean for the field?

Bempedoic acid is a safe, efficacious, and cost-effective therapy to lower LDL-C and cardiovascular risk in high- and very-high-risk patients unable or unwilling to take statins. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

Jakub Michał Zimodro; Ioanna Gouni‐Berthold

doi:10.12997/jla.2026.15.3.381

January 1, 2026Journal of Lipid and AtherosclerosisOpen Access

Bempedoic Acid: From Guidelines to the Real World

View Full Paper

Ask AI

Bookmark

Share

Key result

Bempedoic acid significantly reduces LDL-C and major cardiovascular events in high-risk, statin-intolerant patients.

Figures

Why the study?

Does bempedoic acid reduce LDL-C and cardiovascular risk safely in high- and very-high-risk patients with dyslipidemia, particularly those who are statin-intolerant?

Key Points

To review the basic pharmacology, clinical trial and real-world efficacy and safety, and clinical guideline recommendations for bempedoic acid in managing dyslipidemia.
Synthesized pharmacological mechanisms, clinical practice guidelines, and evidence from clinical trials and real-world studies published through November 2025.
Evaluated cardiovascular outcome trial data from the CLEAR Outcomes trial involving 13,970 statin-intolerant patients at high cardiovascular risk over a median follow-up of 40.6 months.
In the CLEAR Outcomes trial, bempedoic acid reduced mean baseline LDL-C from 139 mg/dL to 107 mg/dL at 6 months compared to 136 mg/dL with placebo.
Treatment significantly lowered the primary four-component composite cardiovascular endpoint compared to placebo (11.7% vs. 13.3%; HR, 0.87; p=0.004).
Significant reductions occurred for key secondary endpoints, including the three-component composite (8.2% vs. 9.5%; HR, 0.85; p=0.006), fatal or nonfatal myocardial infarction (3.7% vs. 4.8%; HR, 0.77; p=0.002), and coronary revascularization (6.2% vs. 7.6%; HR, 0.81; p=0.001).

Structured PICO

Does bempedoic acid reduce LDL-C and cardiovascular risk safely in high- and very-high-risk patients with dyslipidemia, particularly those who are statin-intolerant?

P

Population

This review summarizes clinical trials and real-world studies evaluating the efficacy and safety of bempedoic acid in patients with hypercholesterolemia and those at high cardiovascular risk.

I

Intervention

Bempedoic acid (typically 180 mg once daily, administered orally), used as monotherapy or as a fixed-dose combination with ezetimibe (10 mg), added to background lipid-lowering therapy.

C

Comparator

Placebo or standard background guideline-directed lipid-lowering therapy (such as statins, ezetimibe, or PCSK9 inhibitors) depending on the specific trial.

This comprehensive review demonstrates that bempedoic acid is an effective and well-tolerated non-statin lipid-lowering therapy that significantly reduces LDL-C and cardiovascular events, especially beneficial for statin-intolerant patients.

Limitations

Further studies are required to confirm the magnitude of additional LDL-C reduction when combined with high-intensity statins.
Bempedoic acid is associated with minimal, reversible increases in creatinine and decreases in estimated glomerular filtration rate.
Hyperuricemia and gout are more frequently reported during treatment, requiring monitoring and potential discontinuation if symptoms occur.

Implication

Supports use in statin-intolerant high-risk patients; extends CLEAR Outcomes data into guidelines and real-world settings.

Abstract

Atherosclerotic cardiovascular disease remains the global leading cause of mortality. Hypercholesterolemia is a major, yet mostly insufficiently controlled, cardiovascular risk factor. Guideline-recommended lipid-lowering therapies (LLT) are underutilized, leading to low rates of low-density lipoprotein cholesterol (LDL-C) goal attainment. Poor adherence and intolerance to statins contributed to the need for developing non-statin lipid-lowering drugs. Their role increased following the concept of upfront combination LLT in patients unlikely to reach their LDL-C goal on statin monotherapy. Bempedoic acid emerged as a generally safe, efficient, and cost-effective strategy to lower LDL-C and cardiovascular risk in high- and very-high-risk individuals unable or unwilling to take statins. This updated review 1) outlines the basic pharmacology of bempedoic acid, 2) summarizes the results of clinical trials and real-world studies evaluating the efficacy and safety of bempedoic acid in the treatment of dyslipidemias, and 3) discusses the various current guidelines on the use of bempedoic acid in clinical practice.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Zimodro et al. (2026) conducted a review in Dyslipidemia and Atherosclerotic Cardiovascular Disease. Bempedoic acid vs. Placebo or standard lipid-lowering therapy was evaluated. Bempedoic acid is a safe and effective non-statin therapy that significantly reduces LDL-C levels and the risk of major cardiovascular events in high-risk and statin-intolerant patients.

synapsesocial.com/papers/6ad0fd403afa093ea9ad02b3 https://doi.org/10.12997/jla.2026.15.3.381

Topics

Statin therapy

View Full Paper

Ask AI

Bookmark

Share

Bempedoic Acid: From Guidelines to the Real World

Figures

Key Points

Structured PICO

Limitations

Implication

Abstract

Discussion

Cite This Study

Topics

Bempedoic Acid: From Guidelines to the Real World

Figures

Key Points

Structured PICO

Limitations

Implication

Abstract

Discussion

Cite This Study

Keep reading

Topics

Keep reading